News
MOLN
3.745
-0.95%
-0.036
Molecular Partners Announces Publication In Cancer Immunology Research Of Preclinical Data Supporting MP0533's Proposed Mechanism Of Action
Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cells. Results highlight MP05 33-mediated T-cell activation and tumor regression, as well as cytokine release in AML models. Ongoing Phase 1/2a clinical study continues to progress well.
Benzinga · 2d ago
Weekly Report: what happened at MOLN last week (0422-0426)?
Weekly Report · 2d ago
Weekly Report: what happened at MOLN last week (0415-0419)?
Weekly Report · 04/22 09:12
Life Science Cares Launches in Switzerland
Life Science Cares is a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities. The association has launched in Switzerland, marking its first expansion into geographies outside of the U.S. Life Science Caring is in Switzerland.
Barchart · 04/19 10:12
MOLECULAR PARTNERS ANNOUNCES ALL BOARD PROPOSALS APPROVED AT THE ANNUAL GENERAL MEETING
Reuters · 04/17 15:12
Weekly Report: what happened at MOLN last week (0408-0412)?
Weekly Report · 04/15 09:11
Weekly Report: what happened at MOLN last week (0401-0405)?
Weekly Report · 04/08 09:12
Weekly Report: what happened at MOLN last week (0325-0329)?
Weekly Report · 04/01 09:12
MOLECULAR PARTNERS AG: Report of foreign issuer
Press release · 03/26 16:30
Molecular Partners Sets Date for 2024 AGM
TipRanks · 03/26 13:57
Molecular Partners Publishes Invitation to Annual General Meeting 2024
Barchart · 03/26 08:26
Weekly Report: what happened at MOLN last week (0318-0322)?
Weekly Report · 03/25 09:12
Leerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)
TipRanks · 03/21 06:20
Weekly Report: what happened at MOLN last week (0311-0315)?
Weekly Report · 03/18 09:12
Molecular Partners AG: Strong Financials & Promising Pipeline Justify Buy Rating
TipRanks · 03/15 19:15
Molecular Partners GAAP EPS of -$1.89 beats by $0.14, revenue of $7.0M beats by $1.93M
Seeking Alpha · 03/14 20:21
Molecular Partners FY 2023 GAAP EPS $(2.13) Misses $(2.00) Estimate, Sales $7.894M Beat $5.333M Estimate
Molecular Partners reported quarterly losses of $2.13 per share. The company reported quarterly sales of $7.894 million. This is a 95.98 percent decrease over sales of the same period last year. The firm missed the analyst consensus estimate by 6.6 percent.
Benzinga · 03/14 20:11
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Weekly Report: what happened at MOLN last week (0304-0308)?
Weekly Report · 03/11 09:12
Weekly Report: what happened at MOLN last week (0226-0301)?
Weekly Report · 03/04 09:12
More
Webull provides a variety of real-time MOLN stock news. You can receive the latest news about MOLECULAR PARTNERS AG through multiple platforms. This information may help you make smarter investment decisions.
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.